항레트로바이러스 치료를 받는 한국인 HIV 감염자에서 당뇨병 발생 양상
Clinical manifestations for diabetes mellitus in HIV-infected Koreans on highly active antiretroviral therapy
0
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Background/Aims : The introduction of highly active antiretroviral therapy (HAART) has significantly modified the course of HIV infection. However, the HAART regimens, and especially those including protease inhibitors (PIs), have been shown to cause diabetes mellitus. We evaluated the incidence and clinical manifestations of HIV-infected Koreans who received HAART and the risk factors for diabetes mellitus in those patients. Methods : We conducted a retrospective cohort study and a case-control study to evaluate the clinical manifestations, the incidence and the risk factors for diabetes mellitus in 215 HIV-infected patients who were on HAART at Yonsei University College of Medicine from 1991 to 2006. Results : 215 patients were analyzed and the total duration of follow up was 1079 person-years. The incidences of diabetes mellitus and impaired fasting glucose were 1.39 case/100person-years and 6.02 case/100person-years. Most of the cases were non-obese type II diabetes and these patients showed insulin resistance and impaired β cell function. On the risk factor analysis, the factors contributing to the development of diabetes were age, a decrease of the viral load and indinavir use. Conclusions : In our study, the incidence of diabetes among Korean HIV-positive patients on HAART was 1.39case/100person-years. Age, a decrease of the viral load and indinavir use were the risk factors for development of diabetes mellitus. (Korean J Med 74:506-514, 2008)
Abstract
Background/Aims : The introduction of highly active antiretroviral therapy (HAART) has significantly modified the course of HIV infection. However, the HAART regimens, and especially those including protease inhibitors (PIs), have been shown to cause diabetes mellitus. We evaluated the incidence and clinical manifestations of HIV-infected Koreans who received HAART and the risk factors for diabetes mellitus in those patients. Methods : We conducted a retrospective cohort study and a case-control study to evaluate the clinical manifestations, the incidence and the risk factors for diabetes mellitus in 215 HIV-infected patients who were on HAART at Yonsei University College of Medicine from 1991 to 2006. Results : 215 patients were analyzed and the total duration of follow up was 1079 person-years. The incidences of diabetes mellitus and impaired fasting glucose were 1.39 case/100person-years and 6.02 case/100person-years. Most of the cases were non-obese type II diabetes and these patients showed insulin resistance and impaired β cell function. On the risk factor analysis, the factors contributing to the development of diabetes were age, a decrease of the viral load and indinavir use. Conclusions : In our study, the incidence of diabetes among Korean HIV-positive patients on HAART was 1.39case/100person-years. Age, a decrease of the viral load and indinavir use were the risk factors for development of diabetes mellitus. (Korean J Med 74:506-514, 2008)
참고문헌 (40)
- Moore RD, "Natrual history of HIV infection in the era of combination antiretroviral therapy", AIDS, 13, pp.1933~1942 (1999)
- Herman JS, "The metabolic toxicities of antiretroviral therapy", Int J STD AIDS, 12, pp.555~562 (2001)
- Monier PL, "Metabolic compliations associated with the use of highly active antiretroviral therapy in HIV- 1-infected adults", Am J Med Sci, 328, pp.48~56 (2004)
- Estrada V, "Lipodystrophy and metabolic syndrome in HIV-infected patients treated with antiretroviral therapy", Metabolism, 55, pp.940~945 (2006)
- Havlir DV, "Complications of HIV disease and antiretroviral therapy", Top HIV Med, 14, pp.27~35 (2006)
- Holstein A, "Lipodystrophy and metabolic disorders as complication of antiretroviral therapy of HIV infection", Exp Clin Endocrinol Diabetes, 109, pp.389~392 (2001)
- Mauss S, "Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors", Ann Intern Med, 130, pp.162~163 (1999)
- Salehian B, "Prevalence and incidence of diabetes in HIV-infected minority patients on protease inhibitors", J Natl Med Assoc, 97, pp.1088~1092 (2005)
- Carr A, "Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study", Lancet, 353, pp.2093~2099 (1999)
- Palacios R, "Factors associated with the development of diabetes mellitus in HIV-infected patients on antiretroviral therapy: a case- control study", AIDS, 17, pp.933~935 (2003)
- Saves M, "Factors related to lipodystrophy and metabolic alterations in patients with human immunodeficiency virus infection receiving highly active antiretroviral therapy", Clin Infect Dis, 34, pp.1396~1405 (2002)
- Tsiodras S, "Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: a 5-year cohort study", Arch Intern Med, 160, pp.2050~2056 (2000)
- Behrens G, "Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors", AIDS, 13, pp.63~70 (1999)
- Carr A, "A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors", AIDS, 12, pp.51~58 (1998)
- Justman JE, "Protease inhibitor use and the incidence of diabetes mellitus in a large cohort of HIV-infected women", J Acquir Immune Defic Syndr, 32, pp.298~302 (2003)
- Mehta SH, "The effect of HAART and HCV infection on the development of hyperglycemia among HIV-infected persons", J Acquir Immune Defic Syndr, 33, pp.577~584 (2003)
- Palacios R, "Incidence of and risk factors for insulin resistance in treatment-naive HIV-infected patients 48 weeks after starting highly active antiretroviral therapy", Antivir Ther, 11, pp.529~535 (2006)
- Brown TT, "Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study", Arch Intern Med, 165, pp.1179~1184 (2005)
- Yoon C, "Case-control study of diabetes mellitus in HIV-infected patients", J Acquir Immune Defic Syndr, 37, pp.1464~1469 (2004)
- Kim SM, "Prevalence of diabetes and impaired fasting glucose in Korea: Korean National Health and Nutrition Survey 2001", Diabetes Care, 29, pp.226~231 (2006)
- Kang HW, "Pathophysiologic heterogeneity in the development of type 2 diabetes mellitus in Korean subjects", Diabetes Res Clin Pract, 69, pp.180~187 (2005)
- Kim DJ, "Insulin secretory dysfunction and insulin resistance in the pathogenesis of Korean type 2 diabetes mellitus", Metabolism, 50, pp.590~593 (2001)
- Shin CS, "Risk factors for the development of NIDDM in Yonchon County, Korea.", Diabetes Care, 20, pp.1842~1846 (1997)
- American Diabetes Association, "Diagnosis and classification of diabetes mellitus", Diabetes Care, 27, pp.5~10 (2004)
- Western Pacific Regional Office of the World Health Organization, "The International Obesity Task Force. The Aisa-Pacific perspective: redefining obesity and its treatment. Sydney" (2000), Health Communications Australia
- Alberti KG, "Definition, diagnosis and classification of diabetes mellitus and its complications: part 1. diagnosis and classification of diabetes mellitus provisional report of a WHO consultation", Diabet Med, 15, pp.539~553 (1998)
- Matthews DR, "Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man", Diabetologia, 28, pp.412~419 (1985)
- Sihoon Lee, "Cutoff Values of Surrogate Measures of Insulin Resistance for Metabolic Syndrome in Korean Non-diabetic Adults", Journal of Korean Medical Science, 21(4), pp.695~700 (2006), 대한의학회
- 최영주, "항레트로바이러스 다제요법을 받는 우리나라 HIV 감염환자의 대사합병증", 감염과화학요법, 36(4), pp.197~206 (2004), 대한감염학회
- Zimmet PZ, "Chanlleges in diabetes epidemiology: from West to the rest", Diabetes Care, 15, pp.232~252 (1992)
- Bjorntorp P, "Abdominal obesity and the development of noninsulin-dependent diabetes mellitus", Diabetes Metab Rev, 4, pp.615~622 (1988)
- Rebuffe-Scrive M, "Metabolism of adipose tissue in intraabdominal depots of non-obese men and women", Metabolism, 38, pp.453~458 (1989)
- Bjourntop P, "How should obesity be defined?", J Intern Med, 227, pp.147~149 (1990)
- Megvesi C, "Glucose tolerance and diabetes in chronic liver disease", Lancet, 2, pp.1051~1056 (1967)
- Allison ME, "Evidence for a link between hepatitits C virus infection and diabetes mellitus in a cirrhotic population", J Hepatol, 21, pp.1135~1139 (1994)
- Barbaro G, "Highly active antiretroviral therapy-associated metabolic syndrome: pathogenesis and cardiovascular risk", Am J Ther, 13, pp.248~260 (2006)
- Woerle HJ, "Mechanisms for the deterioration in glucose tolerance associated with HIV protease inhibitor regimens", Diabetes, 52, pp.918~925 (2003)
- Bitnun A, "Insulin sensitivity and beta-cell function in protease inhibitor-treated and -naive human immunodeficiency virus-infected children", J Clin Endocrinol Metab, 90, pp.168~174 (2005)
- Addy CL, "Hypoadiponectinemia is associated with insulin resistance, hypertriglyceridemia, and fat redistribution in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy", J Clin Endocrinol Metab, 88, pp.627~636 (2003)
- Kim RJ, "HIV protease inhibitor-specific alterations in human adipocyte differentiation and metabolism", Obesity, 14, pp.994~1002 (2006)